NeuClone
Australian Technology Park, National Innovation
Centre, 4 Cornwallis Street
Eveleigh
Sydney
New South Wales
2015
Australia
Tel: 612 9209 4020
Website: http://www.neuclone.com/
Email: info@neuclone.com
About NeuClone
NeuClone is a biotechnology company developing and commercialising high quality biosimilars. The company is focused on creating a deep pipeline of clinically identical biosimilars at significantly reduced prices for entry into both new and established markets.
YEAR FOUNDED:
2007
LEADERSHIP:
Founder and CEO: Noelle Sunstrom
CLINICAL TRIAL:
10 articles about NeuClone
-
NeuClone Announces Positive Results from Phase I Study of Stelara® (ustekinumab) Biosimilar Candidate
10/20/2020
NeuClone Pharmaceuticals Ltd (NeuClone) today announced its biosimilar candidate of Stelara ® (ustekinumab), NeuLara, has successfully met all primary and secondary endpoints in a Phase I clinical trial. This includes all pre-specified criteria demonstrating the clinical pharmacokinetic (PK) similarity of NeuLara, compared to US-
-
NeuClone Discloses Two Biosimilars Referencing Opdivo® and Keytruda®
9/1/2020
NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company developing high-quality biosimilar products, today disclosed two additional biosimilars in active development. The products are biosimilar candidates referencing Opdivo ® (nivolumab) and Keytruda ® (pembrolizumab). These biosimilars reference two antibody products that bl
-
BioSpace Global Roundup, April 16
4/16/2020
Global pharma and life sciences companies provide updates on their business operations and pipelines. -
NeuClone Announces Completion of Subject Visits in Stelara® (ustekinumab) Biosimilar Phase I Clinical Trial
4/8/2020
NeuClone Pharmaceuticals Ltd announced successful completion of monitoring visits and blood sampling for subjects in the Phase I clinical trial for its Stelara® biosimilar candidate, NeuLara.
-
NeuClone Announces First Human Dose of Stelara® (Ustekinumab) Biosimilar Candidate in Phase I Clinical Trial
10/17/2019
NeuClone, a clinical-stage biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced it has commenced dosing of Stelara® (ustekinumab) biosimilar candidate, NeuLara, in a Phase I clinical trial.
-
BioSpace Global Roundup, May 16
5/16/2019
Pharma and biotech companies from across the globe provide business and pipeline updates, with news from Gecko, ValGenesis, NeuClone, Zymeworks, and more. -
NeuClone to Initiate Phase I Clinical Trial of Stelara (Ustekinumab) Biosimilar, the Second Biosimilar from the 10-product Portfolio with Serum Institute
5/15/2019
NeuClone Pharmaceuticals Ltd. announced it will initiate the Phase I clinical trial of its Stelara® biosimilar in the second half of 2019.
-
NeuClone Announces its Sixth Biosimilar Candidate Perjeta(R) (Pertuzumab) for use in Combination Therapy with Herceptin(R) (Trastuzumab)
12/17/2018
The product is a biosimilar candidate of Perjeta® (pertuzumab) currently in preclinical development.
-
NeuClone Announces First Human Dose of Herceptin® (trastuzumab) Biosimilar Candidate in Phase I Clinical Trial
10/23/2018
NeuClone Ltd, a biopharmaceutical company exclusively focused on developing high-quality biosimilar products, today announced it has commenced first-in-human dosing of its Herceptin® (trastuzumab) biosimilar candidate, in a Phase I clinical trial.
-
NeuClone Discloses Details of its Fifth Product: a Biosimilar Candidate for Prolia/XGEVA (Denosumab)
1/9/2018
NeuClone Pty. Ltd. today disclosed the fifth biosimilar candidate being developed in its pipeline of mAb products.